Single B cell technology: A powerful tool for fully human monoclonal antibody generation

Fully human antibodies are monoclonal antibodies (mAbs) derived entirely from human genetic material, making them highly suitable for therapeutic applications due to their low immunogenicity and high specificity. They are widely used in treating cancers, autoimmune diseases, infectious diseases, and other conditions. Traditional methods for generating human antibodies, such as phage display or transgenic mice, have limitations in terms of diversity, affinity, and production time. Single B cell technology has emerged as a powerful alternative, enabling the direct isolation and production of fully human antibodies.

Single B cell technology involves the isolation and analysis of individual B cells from human donors, followed by the cloning and expression of their antibody genes. This approach preserves the natural pairing of antibody heavy and light chains, ensuring high specificity and affinity.

Advantages of Single B Cell Technology

One of the key advantages of single B cell technology is its ability to preserve the natural pairing of heavy and light chains, which is often disrupted in other antibody discovery methods. This ensures that the resulting antibodies retain their native structure and function. Additionally, single B cell technology allows for the discovery of rare antibodies that may be missed by bulk screening methods. The technology is particularly useful for identifying antibodies against complex antigens, such as membrane proteins or post-translationally modified targets, which are often challenging to produce recombinantly. Furthermore, the use of human-derived B cells ensures that the antibodies are fully human, reducing the risk of immunogenicity in clinical applications.

Applications in Therapeutic Antibody Development

Single B cell technology has been successfully applied to develop therapeutic antibodies for a wide range of diseases. For example, it has been used to isolate neutralizing antibodies against viral pathogens such as HIV, influenza, and SARS-CoV-2. In oncology, this technology has enabled the discovery of antibodies targeting tumor-specific antigens, leading to the development of novel immunotherapies. Additionally, single B cell technology has been instrumental in identifying autoantibodies in autoimmune diseases, providing insights into disease mechanisms and potential therapeutic targets. The ability to rapidly generate fully human antibodies with high specificity and affinity makes this technology a powerful tool for drug discovery.

Isolation of B Cells from Peripheral Blood, Bone Marrow, or Lymphoid Tissues

The first step in single B cell technology is the isolation of B cells from human sources such as peripheral blood, bone marrow, or lymphoid tissues. Peripheral blood is the most commonly used source due to its accessibility and relatively high B cell content. Bone marrow and lymphoid tissues, such as tonsils or lymph nodes, are alternative sources that may contain a higher frequency of antigen-specific B cells, particularly in the context of chronic infections or immune responses.

Peripheral blood mononuclear cells (PBMCs) are a critical starting material for the production of fully human monoclonal antibodies (mAbs) using single B cell technology. PBMCs, which include lymphocytes (T cells, B cells, and NK cells) and monocytes, are isolated from human peripheral blood via density gradient centrifugation. Among these, B cells are of particular interest because they naturally produce antibodies and harbor the genetic information required for antigen-specific immune responses. Isolating PBMCs allows researchers to access a diverse pool of B cells, including memory B cells and plasmablasts, which have undergone somatic hypermutation and class-switching in response to antigen exposure. These cells encode high-affinity, antigen-specific antibodies, making them ideal candidates for generating fully human mAbs. By isolating single B cells from PBMCs, researchers can directly capture the native pairing of heavy and light chain variable regions, ensuring the production of antibodies with natural specificity and functionality. This approach avoids the limitations of traditional hybridoma technology or phage display, which often involve artificial pairing or non-human systems.

PBMCs are typically isolated via density gradient centrifugation, after which antigen-specific memory B cells or plasmablasts are enriched using fluorescence-activated cell sorting (FACS) or magnetic-activated cell sorting (MACS). These methods often rely on surface markers such as CD19, CD20, and CD27, combined with fluorescently labeled antigens to identify antigen-specific B cells. Single-cell isolation is then achieved using micromanipulation, flow cytometry-based single-cell sorting, or microfluidic platforms, which ensure high precision and viability. Following isolation, the variable regions of immunoglobulin genes are amplified by reverse transcription polymerase chain reaction (RT-PCR) and cloned into expression vectors for recombinant antibody production. Alternatively, single-cell RNA sequencing (scRNA-seq) can be employed to obtain paired heavy and light chain sequences, enabling the synthesis of fully human mAbs.

For RT-PCR, single B cells are lysed, and their mRNA is reverse-transcribed into cDNA. Primers specific to the conserved regions of the VH and VL genes are then used to amplify the variable regions. This approach is cost-effective and widely used but requires careful primer design to ensure coverage of the diverse antibody repertoire.

scRNA-seq offers a more comprehensive approach by capturing the entire transcriptome of single B cells, including the VH and VL genes. This method not only provides sequence information but also enables the analysis of gene expression profiles, which can provide insights into the functional state of the B cell. However, scRNA-seq is more expensive and computationally intensive compared to RT-PCR. Both methods require subsequent cloning of the amplified VH and VL genes into expression vectors for recombinant antibody production.

Recombinant Expression of Antibodies In Vitro

The final step in the process is the recombinant expression of the antibodies in vitro. The amplified VH and VL genes are cloned into expression vectors, typically under the control of strong promoters such as CMV or EF-1α. These vectors are then transfected into host cells, such as HEK293 or CHO cells, for transient or stable expression. Transient expression is often used for initial screening and characterization, while stable expression is preferred for large-scale production.

The expressed antibodies are purified using affinity chromatography, such as protein A or protein G, which binds to the Fc region of human IgG. The purified antibodies are then characterized for binding specificity, affinity, and functional activity using techniques such as ELISA, surface plasmon resonance (SPR), or cell-based assays. If necessary, the antibodies can be further optimized through protein engineering techniques, such as affinity maturation or humanization, to enhance their therapeutic potential.

Challenges and Limitations

Despite its many advantages, single B cell technology faces several challenges. The isolation and sorting of antigen-specific B cells can be technically demanding, particularly for low-abundance targets. The requirement for high-quality starting material, such as fresh blood samples, can also limit its applicability in certain settings. Additionally, the need for sophisticated equipment and expertise in single-cell genomics and bioinformatics may pose barriers to widespread adoption. Furthermore, while single B cell technology is highly effective for discovering antibodies, subsequent steps such as antibody engineering, optimization, and large-scale production remain critical for translating these discoveries into clinically viable therapeutics.

Future Directions

The future of single B cell technology lies in its integration with other advanced methodologies, such as artificial intelligence (AI) and machine learning, to predict antibody-antigen interactions and optimize antibody properties. The development of novel microfluidic platforms and automated workflows is expected to further enhance the throughput and efficiency of single B cell screening. Additionally, the application of single B cell technology in conjunction with CRISPR/Cas9 gene editing holds promise for generating next-generation antibodies with enhanced functionalities, such as bispecific antibodies or antibody-drug conjugates. As the field continues to evolve, single B cell technology is likely to play an increasingly important role in the discovery and development of fully human antibodies for therapeutic use.

References

1. DeKosky, B. J., Kojima, T., Rodin, A., Charab, W., Ippolito, G. C., Ellington, A. D., & Georgiou, G. (2015). In-depth determination and analysis of the human paired heavy- and light-chain antibody repertoire.Nature Medicine, 21(1), 86-91. https://doi.org/10.1038/nm.3743
2. Pedrioli, A., & Oxenius, A. (2021). Single B cell technologies for monoclonal antibody discovery. Trends in Immunology, 42(12), 1143–1158. https://doi.org/10.1016/j.it.2021.10.008
3. Tiller, T., & Meffre, E. (2016). Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning.Journal of Immunological Methods, 329(1-2), 112-124. https://doi.org/10.1016/j.jim.2007.09.017
4. Wardemann, H., & Kofer, J. (2013). Human monoclonal antibody discovery using single B cell technologies.Current Opinion in Immunology, 25(2), 153-159. https://doi.org/10.1016/j.coi.2013.03.004
5. Smith, K., Garman, L., Wrammert, J., Zheng, N.-Y., Capra, J. D., Ahmed, R., & Wilson, P. C. (2009). Rapid generation of fully human monoclonal antibodies specific to a vaccinating antigen.Nature Protocols, 4(3), 372-384. https://doi.org/10.1038/nprot.2009.3